JPH0131414B2 - - Google Patents

Info

Publication number
JPH0131414B2
JPH0131414B2 JP58193331A JP19333183A JPH0131414B2 JP H0131414 B2 JPH0131414 B2 JP H0131414B2 JP 58193331 A JP58193331 A JP 58193331A JP 19333183 A JP19333183 A JP 19333183A JP H0131414 B2 JPH0131414 B2 JP H0131414B2
Authority
JP
Japan
Prior art keywords
dispersion
lipid
liquid
phase
homogenized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP58193331A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5989620A (ja
Inventor
Redojiniatsuku Jeraaru
Meibetsuku Aran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parfums Christian Dior SA
Original Assignee
Parfums Christian Dior SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9278316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0131414(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Parfums Christian Dior SA filed Critical Parfums Christian Dior SA
Publication of JPS5989620A publication Critical patent/JPS5989620A/ja
Publication of JPH0131414B2 publication Critical patent/JPH0131414B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/44—Mixers in which the components are pressed through slits
    • B01F25/441—Mixers in which the components are pressed through slits characterised by the configuration of the surfaces forming the slits
    • B01F25/4413—Mixers in which the components are pressed through slits characterised by the configuration of the surfaces forming the slits the slits being formed between opposed conical or cylindrical surfaces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/44—Mixers in which the components are pressed through slits
    • B01F25/442—Mixers in which the components are pressed through slits characterised by the relative position of the surfaces during operation
    • B01F25/4422—Mixers in which the components are pressed through slits characterised by the relative position of the surfaces during operation the surfaces being maintained in a fixed but adjustable position, spaced from each other, therefore allowing the slit spacing to be varied
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/45—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/924—Significant dispersive or manipulative operation or step in making or stabilizing colloid system
    • Y10S516/929—Specified combination of agitation steps, e.g. mixing to make subcombination composition followed by homogenization
    • Y10S516/93—Low shear followed by high shear
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/783—Organic host/matrix, e.g. lipid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Polymerisation Methods In General (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP58193331A 1982-10-05 1983-10-15 水和脂質カメラ相分散液の均質化方法及びその方法により製造される分散液 Granted JPS5989620A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8217311 1982-10-15
FR8217311A FR2534487B1 (fr) 1982-10-15 1982-10-15 Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede

Publications (2)

Publication Number Publication Date
JPS5989620A JPS5989620A (ja) 1984-05-23
JPH0131414B2 true JPH0131414B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-06-26

Family

ID=9278316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58193331A Granted JPS5989620A (ja) 1982-10-05 1983-10-15 水和脂質カメラ相分散液の均質化方法及びその方法により製造される分散液

Country Status (12)

Country Link
US (1) US4621023A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0107559B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5989620A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE27909T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1228779A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3372174D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK159194C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES526498A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2534487B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR79616B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK49988A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL69911A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2976526B2 (ja) * 1994-06-20 1999-11-10 日本新薬株式会社 乳剤の製法及び乳化機

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
FR2591105B1 (fr) 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
AU598002B2 (en) * 1986-07-15 1990-06-14 Cilag Ltd. Method of preparing single bilayered liposomes
ATE115403T1 (de) * 1987-01-27 1994-12-15 Vestar Inc Aus phospholipiden bestehende darreichungsform für wasserunlösliche wirksubstanzen.
JPS63209746A (ja) * 1987-02-27 1988-08-31 Terumo Corp リポソ−ムの製法
JP2599390B2 (ja) * 1987-06-25 1997-04-09 第一製薬株式会社 安定なリポソーム水分散液
FR2623716B1 (fr) * 1987-11-27 1991-04-05 Lvmh Rech Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la tyrosine ou un derive de tyrosine et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite pigmentante, l'incorporant
US5290562A (en) * 1987-11-27 1994-03-01 L V M H Recherche Compositions and methods employing liposomes including tyrosine or a tyrosine derivative
CH675967A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1987-12-09 1990-11-30 Induchem Ag
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
DE3905354C2 (de) * 1989-02-22 2000-02-10 Reinhold A Brunke Vorrichtung zum Zerkleinern von Liposomen
FR2649335B1 (fr) * 1989-07-05 1991-09-20 Texinfine Sa Procede et dispositif de production directe de liposomes
AU6501390A (en) * 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US20020150539A1 (en) 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5705187A (en) 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
EP0461333B1 (en) * 1990-06-11 1995-03-29 Idi Farmaceutici S.P.A. Phospholipidic liposomes containing active principles and a process for the production thereof
JPH04107319U (ja) * 1991-02-26 1992-09-16 大日本プラスチツクス株式会社 外装材取付構造
FR2673840A1 (fr) * 1991-03-14 1992-09-18 Lvmh Rech Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant de l'oxyacanthine, en particulier destinee a stimuler la pousse des cheveux ou a retarder leur chute.
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
WO1993000156A1 (en) * 1991-06-29 1993-01-07 Miyazaki-Ken Monodisperse single and double emulsions and production thereof
FR2695035A1 (fr) * 1992-08-25 1994-03-04 Lvmh Rech Gie Utilisation d'un ecdystéroïde pour la préparation de compositions cosmétiques ou dermatologiques destinées notamment à renforcer la fonction protectrice de la peau, et compositions ainsi obtenues.
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
WO1994012155A1 (en) * 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process
FR2699081B1 (fr) * 1992-12-11 1995-04-07 Lvmh Rech Utilisation d'un extrait de Simaba pour l'atténuation des taches pigmentaires cutanées ou pour renforcer la fonction protectrice de la peau, ou pour la préparation d'un milieu de culture de cellules de peau, et composition ainsi obtenue.
FR2699080B1 (fr) 1992-12-11 1995-04-07 Lvmh Rech Utilisation d'un extrait de Simarouba pour l'atténuation des taches pigmentaires cutanées ou pour renforcer la fonction protectrice de la peau, ou pour la préparation d'un milieu de culture de cellules de peau, et composition ainsi obtenue.
DE4309971A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Imprägnierungsemulsion für mineralische Baustoffe
US5759571A (en) * 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5492648A (en) * 1993-07-02 1996-02-20 Lau; John R. Organic oil stabilization techniques
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5843334A (en) * 1994-06-20 1998-12-01 Nippon Shinyaku Co., Ltd. Method of producing emulsions and an emulsification apparatus
US7196055B2 (en) 1994-08-31 2007-03-27 Trustees Of Boston University Inhibition of apoptosis in keratinocytes by a ligand of p75 nerve growth factor receptor
US6867179B1 (en) 1994-08-31 2005-03-15 Trustees Of Boston University Methods of inducing hair growth and coloration
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6147056A (en) * 1995-06-06 2000-11-14 Trustees Of Boston University Use of locally applied DNA fragments
US7094766B1 (en) 1995-06-06 2006-08-22 Trustees Of Boston University Use of locally applied DNA fragments
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
NL1001380C2 (nl) * 1995-10-09 1997-04-11 Fuji Photo Film Bv Methode voor het dispergeren van een geëmulgeerd materiaal van het olie-druppeltype in een vloeistoftoevoersysteem en bekledingsmethode waarbij van een dergelijke dispergeermethode gebruik wordt gemaakt.
CZ310798A3 (cs) * 1996-03-28 1999-02-17 Trustees Of Boston University Způsob tlumení aktivace tyrosinasy, upravování pigmentace a identifikace látky, látka zesilující fosforylaci tyrosinasy, látka tlumící fosforylaci tyrosinasy, použití činidla tlumícího fosforylaci tyrosinasy, použití peptidu a použití DNA
JP2001507207A (ja) 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 化合物を細胞に送達する方法
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
PT977597E (pt) 1996-09-11 2003-06-30 Imarx Pharmaceutical Corp Metodos melhorados para imagiologia de diagnosticoutilizando um agente de contraste e um vasodil atador
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
ES2134130B1 (es) * 1997-02-05 2000-04-16 Inst Cientifico Tecnol Navarra Procedimiento y aparato para la produccion de vectores no biologicos de transporte de sustancias por inyeccion coaxial turbulenta.
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
EP1008380B1 (en) 1998-12-07 2004-03-10 F. Hoffmann-La Roche Ag Method and device for mixing or dispersing liquids
EP1274410A2 (en) * 2000-03-31 2003-01-15 Trustees Of Boston University Use of locally applied dna fragments
US20060093661A1 (en) * 2002-05-07 2006-05-04 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
US20030212046A1 (en) * 2002-05-07 2003-11-13 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
EA200200925A1 (ru) * 2002-07-18 2003-04-24 Ооо "Био-3" Способ получения вододисперсионных препаратов жирорастворимых витаминов и антиоксидантов
US20060269924A1 (en) * 2003-04-11 2006-11-30 Trustees Of Boston University Modulation of telomere-initiated cell signaling
US20050153948A1 (en) * 2003-11-20 2005-07-14 Zomanex, Llc Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone
FR2864539B1 (fr) * 2003-12-30 2012-10-26 Lvmh Rech Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee
EP2434009A1 (en) * 2004-05-19 2012-03-28 Trustees of Boston University Modulation of WRN-mediated telomere-initiated cell signaling
PT1835922E (pt) * 2004-12-22 2009-07-08 Merck Serono Sa Tratamento combinado para esclerose múltipla
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US20080124387A1 (en) 2006-11-27 2008-05-29 Kapac, Llc Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients
US20080207711A1 (en) * 2007-02-28 2008-08-28 Rong Li Method for treating an ID2-related disorder
CH715456B1 (de) 2007-04-27 2020-04-30 Mibelle Ag Kosmetisches Produkt zur topischen Anwendung für den Schutz und die Erneuerung von Hautstammzellen, welches sich von dedifferenzierten Pflanzenzellen ableitet.
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
UA96076C2 (en) 2007-10-16 2011-09-26 Репрос Терапьютикс Инк. Use of trans-clomiphene
US8101606B2 (en) * 2007-11-12 2012-01-24 Washington University Neurofibromin pathway modulators
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
CA2675704C (en) 2009-08-18 2010-05-25 The Procter & Gamble Company A method of making a fabric softening composition using a dynamic orifice with a valve in different positions
US8173589B2 (en) 2010-03-18 2012-05-08 The Procter & Gamble Company Low energy methods of making pearlescent fabric softener compositions
CN102906103A (zh) 2010-03-22 2013-01-30 利普生物药剂公司 用于抗孕酮的非毒性递送的组合物和方法
UA113283C2 (xx) 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
US20130084326A1 (en) * 2011-10-03 2013-04-04 Bruce Howe Liposomes for the oral delivery of therapeutic agents
SG11201407397WA (en) 2012-05-31 2014-12-30 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
EP3650546A1 (en) 2015-07-29 2020-05-13 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutic oligonucleotides
EP3124609A1 (en) 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutics oligonucleotides
US12053748B2 (en) 2018-06-14 2024-08-06 Tetra Laval Holdings & Finance S.A. Homogenizer for liquid food
WO2020023340A1 (en) 2018-07-23 2020-01-30 Signalrx Pharmaceuticals, Inc. Single molecule compounds providing multi-target inhibition of btk and other proteins and methods of use thereof
EP3850100B1 (en) 2018-09-12 2024-11-06 The Broad Institute, Inc. Targeting egln1 in cancer
EP4050002A1 (en) 2021-02-26 2022-08-31 First Health Pharmaceuticals B.V. Anti-proliferative agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH366518A (de) * 1959-01-15 1963-01-15 Lendi Wilhelm Homogenisiervorrichtung
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS55140359U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1979-03-29 1980-10-07

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2976526B2 (ja) * 1994-06-20 1999-11-10 日本新薬株式会社 乳剤の製法及び乳化機

Also Published As

Publication number Publication date
ATE27909T1 (de) 1987-07-15
ES8405638A1 (es) 1984-06-16
HK49988A (en) 1988-07-15
DE3372174D1 (en) 1987-07-30
JPS5989620A (ja) 1984-05-23
IL69911A0 (en) 1984-01-31
EP0107559A1 (fr) 1984-05-02
DK159194B (da) 1990-09-17
US4621023A (en) 1986-11-04
DK475483A (da) 1984-04-16
GR79616B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-10-31
CA1228779A (en) 1987-11-03
ES526498A0 (es) 1984-06-16
DK475483D0 (da) 1983-10-14
DE107559T1 (de) 1985-04-25
EP0107559B2 (fr) 1997-12-17
EP0107559B1 (fr) 1987-06-24
FR2534487B1 (fr) 1988-06-10
FR2534487A1 (fr) 1984-04-20
DK159194C (da) 1991-02-25

Similar Documents

Publication Publication Date Title
JPH0131414B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA1208133A (en) Pulverulent mixture of lipidic constituents and hydrop hobic constituents, methods for obtaining the same hyd rated lipidic lamellar phases and method for producing the same, pharmaceutical or cosmetic compositions com prising hydrated lipidic lamellar phases
Sjöström et al. Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesteryl acetate
DE60315489T2 (de) Teilchen erhalten durch extraktion einer emulsion mittels eines superkritischen fluids
Shashidhar et al. Nanocharacterization of liposomes for the encapsulation of water soluble compounds from Cordyceps sinensis CS1197 by a supercritical gas anti-solvent technique
EP2450031B1 (en) Method for producing liposomes by two-stage emulsification method using outer aqueous phase containing specific dispersing agent, method for producing liposome dispersion or dry powder thereof using the method for producing liposomes, and liposome dispersion or dry powder thereof produced thereby
CN108618146A (zh) 由大豆蛋白-甜菊糖苷复合稳定的植物甾醇纳米乳液及其制备方法与应用
EP2368627A1 (en) Method for producing liposome and method for dissolving cholesterol
JP3681776B2 (ja) プロリポソーム及びリポソームの製造方法
WO2013011598A1 (ja) 溶解助剤を利用したリポソーム含有製剤およびその製造方法
JP5494054B2 (ja) 二段階乳化によるリポソーム製造方法
JP5371030B2 (ja) ベシクルの製造方法、この製造方法によって得られるベシクルおよびベシクルを製造するためのｗ／ｏ／ｗエマルション
JP2011104572A (ja) リポソームの製造方法およびフロー製造装置
KR100768151B1 (ko) 에스터화 레시딘을 이용한 나노리포좀
KR101507884B1 (ko) 온도감응성 고분자 지질을 이용하여 친수성 활성물질을 함유한 나노캡슐 농축조성물, 그의 제조방법 및 그를 함유한 화장료 조성물
JP4815575B2 (ja) 複合エマルションの製造方法
KR20200040369A (ko) 하이드로제네이티드 라이소포스파티딜콜린 및 소포로리피드를 이용한 난용성 스핑고리피드의 리포좀 제조 방법
WO2011062255A1 (ja) 混合有機溶媒を油相として用いる二段階乳化によるリポソームの製造方法
CN110368362B (zh) 一种磷脂酰丝氨酸乳剂的制备方法
Sjöström et al. Preparation of submicron drug particles in lecithin-stabilized ow emulsions: I. Model studies of the precipitation of cholesteryl acetate
JP5649074B2 (ja) ナノサイズの一次乳化物を利用する二段階乳化によるリポソーム製造方法
KR100778903B1 (ko) 과량의 친수성 생리활성물질을 함유한 나노 농축 캡슐조성물, 이의 제조방법 및 이를 함유한 화장료 조성물
JP7378929B2 (ja) リポソームの製造方法
EP2698341B1 (en) Continuous method for producing nanoparticles and nanoparticles obtained by means of said method
KR20070037438A (ko) 경구용 제품